Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
2003 1
2004 1
2005 2
2006 1
2007 2
2008 9
2009 11
2010 5
2011 12
2012 23
2013 47
2014 29
2015 12
2016 6
2017 15
2018 7
2019 11
2020 24
2021 40
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 32917784

218 results
Results by year
Filters applied: . Clear all
Page 1
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM; IMPROVE-CKD Trial Investigators. Toussaint ND, et al. J Am Soc Nephrol. 2020 Nov;31(11):2653-2666. doi: 10.1681/ASN.2020040411. Epub 2020 Sep 11. J Am Soc Nephrol. 2020. PMID: 32917784 Clinical Trial.
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C; IMPROVE-CKD Writing Committee.. Lioufas N, et al. BMJ Open. 2019 Feb 21;9(2):e024382. doi: 10.1136/bmjopen-2018-024382. BMJ Open. 2019. PMID: 30796122 Free PMC article. Clinical Trial.
Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Lioufas NM, Pedagogos E, Hawley CM, Pascoe EM, Elder GJ, Badve SV, Valks A, Toussaint ND; on behalf of the IMPROVE-CKD Investigators. Lioufas NM, et al. Am J Nephrol. 2020;51(3):201-215. doi: 10.1159/000505717. Epub 2020 Feb 5. Am J Nephrol. 2020. PMID: 32023606 Clinical Trial.
Effects of phosphate binders in moderate CKD.
Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Block GA, et al. J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19. J Am Soc Nephrol. 2012. PMID: 22822075 Free PMC article. Clinical Trial.
Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G; FRENCH Study collaborators. Liabeuf S, et al. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1930-1940. doi: 10.2215/CJN.03030317. Epub 2017 Oct 26. Clin J Am Soc Nephrol. 2017. PMID: 29074818 Free PMC article. Clinical Trial.
218 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page